HIMS Stock Recent News
HIMS LATEST HEADLINES
Hims stock popped Monday after the FDA reportedly said it would reconsider its decision to bar compounders from selling knockoff tirzepatide.
Shares of Hims & Hers Health Inc (NYSE:HIMS) are popping 10% higher to trade at $20.50 this morning, running higher off good news from the Food and Drug Administration (FDA).
Is Hims & Hers in trouble since the FDA put a time clock on some GLP-1s, or is the future still bright?
Look beyond the stock price at the business when shares are volatile.
Consistently investing even moderate sums can grow your portfolio with time.
The healthcare sector is usually regarded as one of the safest and most stable spaces in the market, which becomes especially important and attractive during volatile periods such as today in the S&P 500 index. However, there is still a preference for the technology sector, and this preference is now being diversified away from the semiconductor industry and into other niches.
Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
NEW YORK , Oct. 4, 2024 /PRNewswire/ -- Hims & Hers Health, Inc. (NYSE:HIMS) will replace Vector Group Ltd (NYSE:VGR) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, October 9. JT Group is acquiring Vector Group in a deal expected to close soon pending final conditions.
Thursday, The FDA determined the shortage of Eli Lilly And Co's LLY tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, has been resolved.